Puesta al día en enfermedad de Crohn perianal

Referencias bibliográficas

• Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003;125(5):1508– 30.
• Vermeire S, Van Assche G, Rutgeerts P. Perianal Crohn’s Disease: classification and clinical evaluation. Dig Liver Dis 2007; 39: 959- 962
• Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology 2006; 130: 650- 656
• Lapidus A, Bernell O, Hellers G, Löfberg R. Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998; 114: 1151-1160
• Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn’s disease phenotyperesults of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008; 103: 3082-3093.
• Cho JH (2008) Me genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8:458–466
• Singh B, McC Mortensen NJ, Jewell DP, et al. Perianal Crohn’s disease. Br J Surg. 2004; 91:801–814.
• Somerville KW, Langman MJ, Da Cruz DJ, et al. Malignant transformation of anal skin tags in Crohn’s disease. Gut. 1984;25:1124–1125.
• Bonheur JL, Braunstein J, Korelitz BI, et al. Anal skin tags in inflammatory bowel disease: new observations and a clinical review. Inflamm Bowel Dis. 2008;14:1236–1239.
• Fleshner PR, Schoetz DJ Jr, Roberts PL, et al. Anal fissure in Crohn’s disease: a plea for aggressive management. Dis Colon Rectum. 1995; 38:1137–1143.
• Sweeney JL, Ritchie JK, Nicholls RJ. Anal fissure in Crohn’s disease. Br J Surg. 1988;75:56–57.
• Bouchard D, Denis J. Anoperineal Crohn’s disease. Acta Endoscop. 1999;29:283–301.
• Sultan S, Azria F, Bauer P, et al. Anoperineal tuberculosis: diagnostic and management considerations in seven cases. Dis Colon Rectum. 2002;45:407–410.
• Figg RE, Church JM. Perineal Crohn’s disease: an indicator of poor prognosis and potential proctectomy. Dis Colon Rectum. 2009;52: 646–650.
• Stringer EE, Nicholson TJ, Armstrong D. Efficacy of topical metroni-dazole (10 percent) in the treatment of anorectal Crohn’s disease. Dis Colon Rectum. 2005;48:970–974.
• Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn’s disease. Gut. 2000;47:436–440.
• Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm Bowel Dis. 2007;13:245–253.
• Hughes LE, Donaldson DR, Williams JG, et al. Local depot methyl-prednisolone injection for painful anal Crohn’s disease. Gastroenterology. 1988;94:709–711.
• Cat H, Sophani I, Lemann M, et al. Cyclosporin treatment of anal and perianal lesions associated with Crohn’s disease. Turk J Gastroenterol. 2003;14:121–127.
• Bouguen G, Trouilloud I, Siproudhis L, et al. Long-term outcome of non-fistulizing (ulceration, stricture) perianal Crohn’s disease in patients treated with infliximab. Aliment Pharmacol Mer. 2009;30: 749–756.
• Teahon K, Bjarnason I, Pearson M, et al. Ten years’ experience with an elemental diet in the management of Crohn’s disease. Gut. 1990; 31:1133–1137.
• Guagnozzi D, González-Castillo S, Olveira A, Lucendo AJ. Nutritional treatment in inflammatory bowel disease. An update. Rev Esp Enferm Dig. 2012 Oct;104(9):479-488.
• D’Ugo S, Franceschilli L, Cadeddu F, Leccesi L, Blanco Gdel V, Calabrese E, Milito G, Di Lorenzo N, Gaspari AL, Sileri P. Medical and surgical treatment of haemorrhoids and anal fissure in Crohn’s disease: a critical appraisal. BMC Gastroenterol. 2013 Mar 11;13:47. doi: 10.1186/1471-230X-13-47.
• Fields S, Rosainz L, Korelitz BI, et al. Rectal strictures in Crohn’s disease and coexisting perirectal complications. Inflamm Bowel Dis. 2008;14:29–31.
• Galandiuk S, Kimberling J, Al-Mishlab TG, et al. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg. 2005;241: 796–801; discussion 801–802.
• Linares L, Moreira LF, Andrews H, et al. Natural history and treatment of anorectal strictures complicating Crohn’s disease. Br J Surg. 1988;75:653–655.
• McCloud JM, Jameson JS, Scott ND. Life-threating sepsis following treatment for haemorrhoids: a systematic review. Colorectal Dis. 2006;8:748–755
• Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sand- born WJ, Sutherland LR. A simple classi;cation of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15
• Satsangi J, Silverberg MS, Vermeire S, Colombel JF. Me Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753
• Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981–987.
• Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27–32.
• Nielsen OH, Rogler G, Hahnloser D, Momsen OØ. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol 2009; 6: 92-106
• Taxonera C, Schwartz DA, García-Olmo D. Emerging treatments for complex perianal fistula in Crohn’s disease. World J Gastroenterol 2009; 15: 4263-4272
• Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, Zinsmeister AR, Norton ID, Boardman LA, Devine RM, WolN BG, Young-Fadok TM, Diehl NN, Pemberton JH, Sandborn WJ. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gas- troenterology 2001; 121: 1064-1072
• Karmiris K, Bielen D, Vanbeckevoort D, et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn’s disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011;9:130–6.
• Savoye-Collet C, Savoye G, Koning E, et al. Fistulizing perianal Crohn’s disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis 2011;17:1751–8.
• Ruffolo C, Scarpa M, Faggian D, Pozza A, Navaglia F, D’ Incà R, Hoxha P, Romanato G, Polese L, Sturniolo GC, Plebani M, D’Amico DF, Angriman I. Cytokine network in rectal mucosa in perianal Crohn’s disease: relations with inflammatory parameters and need for surgery. Inflamm Bowel Dis 2008; 14: 1406-1412
• Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398-1405
• Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo- controlled trial. Gastroenterology 2003; 125: 380-388
• Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982; 83: 383-387
• Solomon MJ, McLeod RS, O’Connor BI, Steinhart AH, Greenberg GR, Cohen Z. Combination ciprofloxacin and metronidazole in severe perianal Crohn’s disease. Can J Gas- troenterol 1993; 7: 571-573
• Mia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo- controlled pilot study. Inflamm Bowel Dis 2009; 15: 17-24
• Maeda Y, Ng SC, Durdey P, Burt C, Torkington J, Rao PK, Mayberry J, Moshkovska T, Stone CD, Carapeti E, Vaizey CJ; Topical Metronidazole in Perianal Crohn’s Study Group. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn’s disease. Br J Surg. 2010 Sep;97(9):1340-7. doi: 10.1002/ bjs.7121.
• Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Mer 2003; 18: 1113-1120
• West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, Kuipers EJ. Clinical and endo-sonographic effect of ciprofloxacin on the treatment of peri-anal fistulae in Crohn’s disease with infliximab: a double-blind placebocontrolled study. Aliment Pharmacol Mer 2004; 20: 1329-1336
• Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-142
• Nielsen OH, Rogler G, Hahnloser D, Momsen. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol 2009; 6: 92-106
• Sandborn W. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 48-63
• Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125: 380-388
• Soon SY, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004; 16: 921-926
• Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn’s disease. N Engl J Med 2005; 352: 2193-2201
• Wenzl HH, Hinterleitner TA, Aichbichler BW, Fickert P, Pe tritsch W. Mycophenolate mofetil for Crohn’s disease: short- erm effcacy and long-term outcome. Aliment Pharmacol Mer 2004; 19: 427-434
• Plamondon S, Ng SC, Kamm MA. Malidomide in luminal and fistulizing Crohn’s disease resistant to standard therapies. Aliment Pharmacol Mer 2007; 25: 557-567
• Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA. Effcacy and safety of short-term adalimumab treatment in patients with active Crohn’s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Mer 2007; 25: 409-418
• Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876-885
• El-Gazzaz G, Hull T, Church JM. Biological immunomodulators improve the healing rate in surgically treated perianal Crohn’s fistulas. Colorectal Dis. 2012 Oct;14(10):1217-23.
• Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Long-term Outcome of Perianal Fistulizing Crohn’s Disease Treated With Infliximab. Clin Gastroenterol Hepatol. 2013 Jan 30. pii: S1542-3565(13)00130- 4.
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human antitumor necrosis factor monoclonal antibody (adalimum- ab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591
• Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D’Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838
• Schwartz DA, Rutgeerts P, Colombel JF, Sandborn WJ, Hanauer SB, Kent JD, Pollack PF. Induction, maintenance, and sustainability of the healing of draining fistulas in patients with Crohn’s disease treated with adalimumab: results of the CHARM study. Am J Gastroenterol 2006; 101 (Suppl 9): 1177
• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657
• Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007; 357: 228-238
• Ng SC, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, Kamm MA. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn’s perineal fistulas. Am J Gastroenterol 2009; 104: 2973- 2986
• Meis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Mer 2008; 27: 19-30
• Fukuda Y, Takazoe M, Sugita A, Kosaka T, Kinjo F, Otani Y, Fujii H, Koganei K, Makiyama K, Nakamura T, Suda T, Yamamoto S, Ashida T, Majima A, Morita N, Murakami K, Oshitani N, Takahama K, Tochihara M, Tsujikawa T, Wata-nabe M. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn’s disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2008; 103: 1721-1729
• Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D’Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Ko-letzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis 2010; 4: 63-101
• 6Williams JG, Farrands PA, Williams AB, Taylor BA, Lun-niss PJ, Sagar PM, Varma JS, George BD. The treatment of anal fistula: ACPGBI position statement. Colorectal Dis 2007; 9 Suppl 4: 18-50
• Sangwan YP, Schoetz DJ Jr, Murray JJ, Roberts PL, Coller JA. Perianal Crohn’s disease. Results of local surgical treatment. Dis Colon Rectum 1996; 39: 529-535
• Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-in-ano in Crohn’s disease. Results of aggressive surgical treatment. Dis Colon Rectum 1991; 34: 378-384
• van der Hagen SJ, Baeten CG, Soeters PB, Beets-Tan RG, Russel MG, van Gemert WG. Staged mucosal advancement flap for the treatment of complex anal fistulas: pretreatment with noncutting Setons and in case of recurrent multiple abscesses a diverting stoma. Colorectal Dis 2005; 7: 513-518
• Buchanan GN, Owen HA, Torkington J, Lunniss PJ, Nich- olls RJ, Cohen CR. Long-term outcome following loose-seton technique for external sphincter preservation in com-plex anal fistula. Br J Surg 2004; 91: 476-480
• Hyman N. Endoanal advancement flap repair for complex anorectal fistulas. Am J Surg 1999; 178: 337-340
• Joo JS, Weiss EG, Nogueras JJ, Wexner SD. Endorectal advancement flap in perianal Crohn’s disease. Am Surg 1998; 64: 147-150
• Mizrahi N, Wexner SD, Zmora O, Da Silva G, Efron J, Weiss EG, Vernava AM 3rd, Nogueras JJ. Endorectal advancement flap: are there predictors of failure? Dis Colon Rectum 2002; 45: 1616- 1621
• Edwards CM, George BD, Jewell DP, Warren BF, Mortensen NJ, Kettlewell MG. Role of a defunctioning stoma in the management of large bowel Crohn’s disease. Br J Surg 2000; 87: 1063- 1066
• Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn’s disease. World J Surg 2000; 24: 1258- 1262; discussion 1262-1263
• Mueller MH, Geis M, Glatzle J, Kasparek M, Meile T, Jehle EC, Kreis ME, Zittel TT. Risk of fecal diversion in complicated perianal Crohn’s disease. J Gastrointest Surg 2007; 11: 529-537
• Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg 2005; 241: 796-801; discussion 801-802
• Collie MH, Potter MA, Bartolo DC. Myocutaneous flaps promote perineal healing in inflammatory bowel disease. Br J Surg 2005; 92: 740-741
• Schaden D, Schauer G, Haas F, Berger A. Myocutaneous flaps and proctocolectomy in severe perianal Crohn’s disease--a single stage procedure. Int J Colorectal Dis 2007; 22: 1453-1457
• Bell SW, Dehni N, Chaouat M, Lifante JC, Parc R, Tiret E. Primary rectus abdominis myocutaneous flap for repair of perineal and vaginal defects after extended abdominoperineal resection. Br J Surg 2005; 92: 482-486
• Ruffolo C, Penninckx F, Van Assche G, Vermeire S, Rutg- eerts P, Coremans G, D’Hoore A. Outcome of surgery for rectovaginal fistula due to Crohn’s disease. Br J Surg 2009; 96: 1190-1195
• Ruffolo C, Scarpa M, Bassi N, Angriman I. A systematic review on advancement flaps for rectovaginal fistula in Crohn’ s disease: transrectal vs transvaginal approach. Colorectal Dis 2010; 12: 1183- 1191
• van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets Tan RG, van Gemert WG. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn’s disease: a preliminary report. Dis Colon Rectum 2005; 48: 758-767
• Spradlin NM, Wise PE, Herline AJ, Muldoon RL, Rosen M, Schwartz DA. A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for Crohn’s perianal fistulas. Am J Gastroenterol 2008; 103: 2527-2535
• Moy J, Bodzin J. Carbon dioxide laser ablation of perianal fistulas in patients with Crohn’s disease: experience with 27 patients. Am J Surg 2006; 191: 424-427
• Hammond TM, Grahn MF, Lunniss PJ. Fibrin glue in the management of anal fistulae. Colorectal Dis 2004; 6: 308-319
• Cirocchi R, Farinella E, La Mura F, Cattorini L, Rossetti B, Milani D, Ricci P, Covarelli P, Coccetta M, Noya G, Sciannameo F. Fibrin glue in the treatment of anal fistula: a systematic review. Ann Surg Innov Res 2009; 3: 12
• Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn’s disease. N Engl J Med 1999; 340: 239-240
• El-Gazzaz GS, Zutshi M, Hull TL. Plugging away at the anal fistula: an exercise in futility? Gastroenterology 2008; 134: A862
• Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007; 13: 245-253
• Poggioli G, Laureti S, Pierangeli F, Rizzello F, Ugolini F, Gionchetti P, Campieri M. Local injection of Infliximab for the treatment of perianal Crohn’s disease. Dis Colon Rectum 2005; 48: 768-774
• Tonelli F, Giudici F, Asteria CR. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn’s disease: a pilot study. Dis Colon Rectum. 2012 Aug;55(8):870-5.
• García-Olmo D, García-Arranz M, García LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, GarcíaSancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy. Int J Colorectal Dis 2003; 18: 451-454
• Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del- Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009; 52: 79-86